apitegromab

apitegromab: developed by 1 company · 2 FDA decisions. Updated within the last hour.

Development Pipeline (1)

FDA Decisions

FDA_MeetingBased on the November 12, 2025 Type A Meeting and information from Catalent Indiana, the Company anticipates resubmission of its BLA and U.S. launch of apitegromab in SMA in 2026.(SRRK)

Frequently asked questions

Who is developing apitegromab?

apitegromab is being developed by Scholar Rock Holding Corp.

What is apitegromab's latest FDA decision?

The most recent tracked FDA decision for apitegromab is FDA_Meeting for Based on the November 12, 2025 Type A Meeting and information from Catalent Indiana, the Company anticipates resubmission of its BLA and U.S. launch of apitegromab in SMA in 2026., dated November 12, 2025.

Get deeper analysis on apitegromab

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    apitegromab — Drug Pipeline, Trials & FDA Status | BioSniper